Showing 1 - 20 results of 493 for search '"НОВООБРАЗОВАНИЕ"', query time: 0.86s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
    Academic Journal

    Contributors: The work was carried out within the framework of the budget project on the topic “Development of a test system for the assessment and subsequent correction of the ferroptosis status in hematopoietic stem cells of the aging human body” (project No. 2025-5)., Работа выполнена в рамках бюджетного проекта по теме «Разработка тест-системы для оценки и последующей коррекции статуса ферроптоза в гемопоэтических стволовых клетках стареющего организма человека» (проект № 2025-5).

    Source: Advances in Molecular Oncology; Vol 12, No 3 (2025); 26-35 ; Успехи молекулярной онкологии; Vol 12, No 3 (2025); 26-35 ; 2413-3787 ; 2313-805X

    File Description: application/pdf

  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
    Academic Journal

    Contributors: The publication was prepared with the sponsorship of Roshe., Публикация подготовлена при спонсорской поддержке компании Roshe.

    Source: Head and Neck Tumors (HNT); Том 14, № 4 (2024); 10-23 ; Опухоли головы и шеи; Том 14, № 4 (2024); 10-23 ; 2411-4634 ; 2222-1468

    File Description: application/pdf

    Relation: https://ogsh.abvpress.ru/jour/article/view/1020/647; Salivary-glands. Сancer today. GLOBOCAN, 2022. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/2-salivary-glands-fact-sheet.pdf.; WHO classififcation of tumours editorial board. Head and neck tumours. 5th edn. Lyon: IARC, 2022.; Skalova A., Hyrcza M.D., Leivo I. Update from the 5th edition of the world health organization classification of head and neck tumors: salivary glands. Head Neck Pathol 2022;16(1):40–53. DOI:10.1007/s12105-022-01420-1; Rossi E.D., Baloch Z., Pusztaszeri M., Faquin W.C. The Milan system for reporting salivary gland cytopathology (MSRSGC): an ASC-IAC-sponsored system for reporting salivary gland fineneedle aspiration. J Am Soc Cytopathol 2018;7(3):111–8. DOI:10.1016/j.jasc.2018.02.002; Toper M.H., Sarioglu S. Molecular pathology of salivary gland neoplasms: diagnostic, prognostic, and predictive perspective. Adv Anat Pathol 2021;28(2):81–93. DOI:10.1097/PAP.0000000000000291; Andreasen S., Kiss K., Mikkelsen L.H. et al. An update on head and neck cancer: new entities and their histopathology, molecular background, treatment, and outcome. APMIS 2019;127(5):240–64. DOI:10.1111/apm.12901; Żurek M., Fus Ł., Niemczyk K., Rzepakowska A. Salivary gland pathologies: evolution in classification and association with unique genetic alterations. Eur Arch Otorhinolaryngol 2023;280(11): 4739–50. DOI:10.1007/s00405-023-08110-w; Locati L.D., Ferrarotto R., Licitra L. et al. Current management and future challenges in salivary glands cancer. Front Oncol 2023;13:1264287. DOI:10.3389/fonc.2023.1264287; Laurie S.A., Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 2006;24(17):2673–8. DOI:10.1200/JCO.2005.05.302; Airoldi M., Pedani F., Succo G. et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatinin patients with recurrent salivary gland malignancies. Cancer 2001;91(3): 541–7. DOI:10.1002/1097-0142(20010201)91:33.0.co;2-y; Gilbert J., Li Y., Pinto H.A. et al. Phase II trial of taxol in salivarygland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck 2006;28(3):197–204. DOI:10.1002/hed.20327; Suen J.Y., Johns M.E. Chemotherapy for salivary gland cancer. Laryngoscope 1982;92(3):235–9. DOI:10.1288/00005537-198203000-00003; Ferrarotto R., Heymach J.V. Taking it up a NOTCH: a novel subgroup of ACC is identified. Oncotarget 2017;8(47):81725–6. DOI:10.18632/oncotarget.20879; Ferrarotto R., Mitani Y., Diao L. et al. Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to notch1 inhibitors. J Clin Oncol 2017;35(3):352–60. DOI:10.1200/JCO.2016.67.5264; Ferrarotto R., Mitani Y., McGrail D.J. et al. Proteogenomic analysis of salivary adenoid cystic carcinomas defines molecular subtypes and identifies therapeutic targets. Clin Cancer Res 2021;27(3):852–64. DOI:10.1158/1078-0432.CCR-20-1192; Ferrarotto R., Eckhardt G., Patnaik A. et al. A phase I doseescalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol 2018;29(7):1561–8. DOI:10.1093/annonc/mdy171; Ferrarotto R. 1789P The gamma secretase inhibitor AL101 combined with other drugs for dual targeting of Notch dysregulated tumors. Ann Oncol 2021;32:S1222. DOI:10.1016/j.annonc.2021.08.1732; Ferrarotto R. Results of ACCURACY: a phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/ metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut). J Clin Oncol 2022;40:6046. DOI:10.1200/JCO.2022.40.16_suppl.6046; Humtsoe J.O., Kim H.S., Leonard B. et al. Newly identified members of FGFR1 splice variants engage in cross-talk with AXL/ AKT axis in salivary adenoid cystic carcinoma. Cancer Res 2021;81(4):1001–13. DOI:10.1158/0008-5472.CAN-20-1780; Ferrarotto R., Sousa L.G., Feng L. et al. Phase II clinical trial of axitinib and avelumab in patients with recurrent/metastatic adenoid cystic carcinoma. J Clin Oncol 2023;41(15):2843–51. DOI:10.1200/JCO.22.02221; Tchekmedyian V., Sherman E.J., Dunn L. et al. Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol 2019;37(18):1529–37. DOI:10.1200/JCO.18.01859; Cavalieri S., Platini F., Bergamini C. et al. Genomics in nonadenoid cystic group of salivary gland cancers: one or more druggable entities? Expert Opin Investig Drugs 2019;28(5):435–43. DOI:10.1080/13543784.2019.1598376; Boon E., van Boxtel W., Buter J. et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in the Netherlands. Head Neck 2018;40(3):605–13. DOI:10.1002/hed.25035; Locati L.D., Cavalieri S., Bergamini C. et al. Abiraterone acetate in patients with castration-resistant, androgen receptor-expressing salivary gland cancer: a phase II trial. J Clin Oncol 2021;39(36):4061–8. DOI:10.1200/JCO.21.00468; Haddad R., Colevas A.D., Krane J.F. et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003;39(7):724–7. DOI:10.1016/s1368-8375(03)00097-6; Takahashi H., Tada Y., Saotome T. et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol 2019;37(2):125–34. DOI:10.1200/JCO.18.00545; Di Villeneuve L., Souza I.L., Tolentino F.D.S. et al. Salivary gland carcinoma: novel targets to overcome treatment resistance in advanced disease. Front Oncol 2020;10:580141. DOI:10.3389/fonc.2020.580141; Skalova A., Vanecek T., Martinek P. et al. Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation: report of 10 cases. Am J Surg Pathol 2018;42(2):234–46. DOI:10.1097/PAS.0000000000000972; Skálová A., Vanecek T., Simpson R.H. et al. Mammary analogue secretory carcinoma of salivary glands: molecular analysis of 25 ETV6 gene rearranged tumors with lack of detection of classical ETV6-NTRK3 fusion transcript by standard RT-PCR: report of 4 cases harboring ETV6-X gene fusion. Am J Surg Pathol 2016;40(1):3–13. DOI:10.1097/PAS.0000000000000537; Drilon A., Li G., Dogan S. et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6- NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol 2016;27(5):920–6. DOI:10.1093/annonc/mdw042; Le X., Baik C., Bauman J. et al. Larotrectinib treatment for patients with TRK fusion-positive salivary gland cancers. Oncologist 2022;29(6):e779–88. DOI:10.1093/oncolo/oyac080; Hyman D.M., Tilburg C.M., Albert C.M. et al. Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer. Ann Oncol 2019;30:v159–93.; Ardini E., Menichincheri M., Banfi P. et al. Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther 2016;15(4):628–39. DOI:10.1158/1535-7163.MCT-15-0758; Rolfo C., Dziadziuszko R., Doebele R.C. et al. 476 PUpdated efficacy and safety of entrectinib in patients with NTRK fusionpositive tumors: integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann Oncol 2019;30:v159–93. DOI:10.1093/annonc/mdz244.038; Lu S., De Braud F.G.M., Fan Y. et al. Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours. Ann Oncol 2023;34(Suppl 2):S458–97. DOI:10.1016/S0923-7534(23)01936-1; Imamura Y., Kiyota N., Tahara M. et al. Systemic therapy for salivary gland Malignancy: current status and future perspectives. Jpn J Clin Oncol 2022;52(4):293–302. DOI:10.1093/jjco/hyac008; Linxweiler M., Kuo F., Katabi N. et al. The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype. Clin Cancer Res 2020;26(12):2859–70. DOI:10.1158/1078-0432.CCR-19-3758; Cohen R.B., Delord J.P., Doi T. et al. Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study. Am J Clin Oncol 2018;41(11):1083–8. DOI:10.1097/COC.0000000000000429; Fayette J., Even C., Digue L. et al. NISCAHN: a phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the Unicancer Head & Neck Group. J Clin Oncol 2019;37:6083. DOI:10.1200/JCO.2019.37.15_suppl.6083; Even C., Delord J.P., Price K.A. et al. Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study. Eur J Cancer 2022;171:259–68. DOI:10.1016/j.ejca.2022.05.007; Niwa K., Kawakita D., Nagao T. et al. Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma. Sci Rep 2020;10(1):16988. DOI:10.1038/s41598-020-73965-6; Vos J.L., Burman B., Jain S. et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial. Nat Med 2023;29(12):3077–89. DOI:10.1038/s41591-023-02518-x; Van Herpen C., Vander Poorten V., Skalova A. et al. Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO Open 2022;7(6):100602. DOI:10.1016/j.esmoop.2022.100602; Kurzrock R., Bowles D.W., Kang H. et al. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol 2020;31(3):412–21. DOI:10.1016/j.annonc.2019.11.018; https://ogsh.abvpress.ru/jour/article/view/1020

  11. 11
    Academic Journal

    Source: Meditsinskiy sovet = Medical Council; № 23 (2024); 256-265 ; Медицинский Совет; № 23 (2024); 256-265 ; 2658-5790 ; 2079-701X

    File Description: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/8720/7762; Csernok E, Gross WL. Current understanding of the pathogenesis of granulomatosis with polyangiitis (Wegener’s). Expert Rev Clin Immunol. 2013;9(7):641–648. https://doi.org/10.1586/1744666X.2013.811052.; Singer O, McCune WJ. Update on maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. Curr Opin Rheumatol. 2017;29(3):248–253. https://doi.org/10.1097/BOR.0000000000000382.; Robson JC, Grayson PC, Ponte C, Suppiah R, Craven A, Judge A et al. DCVAS Investigators. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis. 2022;81(3):315–320. https://doi.org/10.1136/annrheumdis-2021-221795.; Moin KA, Yeakle MM, Parrill AM, Garofalo VA, Tsiyer AR, Bishev D et al. Ocular and orbital manifestations of granulomatosis with polyangiitis: a systematic review of published cases. Rom J Ophthalmol. 2023;67(3):214–221. https://doi.org/10.22336/rjo.2023.38.; Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol. 2021;73(8):1366–1383. https://doi.org/10.1002/art.41773.; Lynch JP 3rd, Derhovanessian A, Tazelaar H, Belperio JA. Granulomatosis with polyangiitis (Wegener’s Granulomatosis): evolving concepts in treatment. Semin Respir Crit Care Med. 2018;39(4):434–458. https://doi.org/10.1055/s-0038-1660874.; Spanuchart I, Zungsontiporn N, O-charoen P, Changcharoen B, Bolger DT Jr. Granulomatosis with polyangiitis: a case of nasal mass, necrotic lung, and normal kidneys. Hawaii J Med Public Health. 2015;74(9 Suppl. 2):27–29. Available at: https://pubmed.ncbi.nlm.nih.gov/26793412.; Binda V, Moroni G, Messa P. ANCA-associated vasculitis with renal involvement. J Nephrol. 2018;31(2):197–208. https://doi.org/10.1007/s40620-017-0412-z.; Banerjee P, Jain A, Kumar U, Senapati S. Epidemiology and genetics of granulomatosis with polyangiitis. Rheumatol Int. 2021;41(12):2069–2089. https://doi.org/10.1007/s00296-021-05011-1.; Tee QX, Wong A, Nambiar M, Lau KK. Granulomatosis with polyangiitis: common and uncommon presentations. J Med Imaging Radiat Oncol. 2022;66(8):1089–1096. https://doi.org/10.1111/1754-9485.13471.; Greco A, Marinelli C, Fusconi M, Macri GF, Gallo A, De Virgilio A et al. Clinic manifestations in granulomatosis with polyangiitis. Int J Immunopathol Pharmacol. 2016;29(2):151–159. https://doi.org/10.1177/0394632015617063.; Grygiel-Górniak B, Limphaibool N, Perkowska K, Puszczewicz M. Clinical manifestations of granulomatosis with polyangiitis: key considerations and major features. Postgrad Med. 2018;130(7):581–596. https://doi.org/10.1080/00325481.2018.1503920.; Byszewska A, Skrzypiec I, Rymarz A, Niemczyk S, Rękas M. Ocular involvement of granulomatosis with polyangiitis. J Clin Med. 2023;12(13):4448. https://doi.org/10.3390/jcm12134448.; Ismailova DS, Abramova JV, Novikov PI, Grusha YO. Clinical features of different orbital manifestations of granulomatosis with polyangiitis. Graefes Arch Clin Exp Ophthalmol. 2018;256(9):1751–1756. https://doi.org/10.1007/s00417-018-4014-9.; Sattui SE, Lally L. Localized granulomatous with polyangiitis (GPA): varied clinical presentations and update on treatment. Curr Allergy Asthma Rep. 2020;20(10):56. https://doi.org/10.1007/s11882-020-00953-1.; Monteiro M, Domingos R, Rocha S, Miranda I. Granulomatosis with polyangiitis: the complexity of clinical manifestations, therapeutic challenges, and complications of a severe multisystemic case. Cureus. 2023;15(10):e47031. https://doi.org/10.7759/cureus.47031.; Redondo-Rodriguez R, Mena-Vázquez N, Cabezas-Lucena AM, Manrique-Arija S, Mucientes A, Fernández-Nebro A. Systematic review and metaanalysis of worldwide incidence and prevalence of antineutrophil cytoplasmic antibody (ANCA) associated vasculitis. J Clin Med. 2022;11(9):2573. https://doi.org/10.3390/jcm11092573.; Bataille PM, Durel CA, Chauveau D, Panes A, Thervet ÉS, Terrier B. Epidemiology of granulomatosis with polyangiitis and microscopic polyangiitis in adults in France. J Autoimmun. 2022;133:102910. https://doi.org/10.1016/j.jaut.2022.102910.; Lutalo PM, D’Cruz DP. Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener’s granulomatosis). J Autoimmun. 2014;48-49:94–98. https://doi.org/10.1016/j.jaut.2014.01.028.; Comarmond C, Cacoub P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun Rev. 2014;13(11):1121–1125. https://doi.org/10.1016/j.autrev.2014.08.017.; Puéchal X. Granulomatosis with polyangiitis (Wegener’s). Joint Bone Spine. 2020;87(6):572–578. https://doi.org/10.1016/j.jbspin.2020.06.005.; Новикова АВ, Правдюк НГ, Шмидт ЕИ, Ракша АП, Мазра МР, Юняев АР, Жулина ЮС. Гранулематоз с полиангиитом: оптимальные возможности быстрой диагностики в многопрофильном стационаре. Клиницист. 2022;16(4):45–55. https://doi.org/10.17650/1818-8338-2022-16-3-К673.; Catanoso M, Macchioni P, Boiardi L, Manenti L, Tumiati B, Cavazza A, et al. Epidemiology of granulomatosis with polyangiitis (Wegener’s granulomatosis) in Northern Italy: a 15-year population-based study. Semin Arthritis Rheum. 2014;44(2):202–207. https://doi.org/10.1016/j.semarthrit.2014.05.005.; Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum. 2003;49(3):388–393. https://doi.org/10.1002/art.11115.; Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum. 2005;53(1):93–99. https://doi.org/10.1002/art.20928.; Gajic-Veljic M, Nikolic M, Peco-Antic A, Bogdanovic R, Andrejevic S, Bonaci-Nikolic B. Granulomatosis with polyangiitis (Wegener’s granulomatosis) in children: report of three cases with cutaneous manifestations and literature review. Pediatr Dermatol. 2013;30(4):e37-е42. https://doi.org/10.1111/pde.12034.; Fouka E, Drakopanagiotakis F, Steiropoulos P. Pathogenesis of pulmonary manifestations in ANCA-associated vasculitis and Goodpasture syndrome. Int J Mol Sci. 2024;25(10):5278. https://doi.org/10.3390/ijms25105278.; Wegener F. Wegener’s granulomatosis. Thoughts and observations of a pathologist. Eur Arch Otorhinolaryngol. 1990;247(3):133–142. https://doi.org/10.1007/BF00175962.; Peixoto L, Aguiar P, Veloso F, Espirito J, Marques N, Jesus I et al. Wegener’s granulomatosis. Advances in the etiology, pathogenesis and pathology of vasculitis. InTech. 2011;11:225–234. http://doi.org/10.5772/20014.; Баранова ЮР, Романова ИА, Стешенко РН, Мелехина ИФ, Никитина НМ, Кароли НА. Гранулематоз Вегенера: трудности диагностики и лечения. Южно-Российский журнал терапевтической практики. 2023;4(4):95–100. https://doi.org/10.21886/2712-8156-2023-4-4-95-100.; Iorio L, Pizzi M, Cecchin D, Davanzo F, Ghirardello A, Dei Tos AP et al. Cutting-edge strategies for renal tumour-like lesions in granulomatosis with polyangiitis: a systematic review. Diagnostics. 2024;14(5):566. https://doi.org/10.3390/diagnostics14050566.; Sfiniadaki E, Tsiara I, Theodossiadis P, Chatziralli I. Ocular manifestations of granulomatosis with polyangiitis: a review of the literature. Ophthalmol Ther. 2019;8(2):227–234. https://doi.org/10.1007/s40123-019-0176-8.; Tarabishy AB, Schulte M, Papaliodis GN, Hoffman GS. Wegener’s granulomatosis: clinical manifestations, differential diagnosis, and management of ocular and systemic disease. Surv Ophthalmol. 2010;55(5):429–444. https://doi.org/10.1016/j.survophthal.2009.12.003.; Лазарчук АВ, Исмаилова ДС. Современные подходы к лечению поражения органа зрения при гранулематозе с полиангиитом (Вегенера). Вестник Совета молодых ученых и специалистов Челябинской области. 2022;1(3):23–30. Режим доступа: https://www.elibrary.ru/sakdqa.; Andrada-Elena M, Ioana TT, Mihaela FM, Irina-Elena C, Andrei TI, Florian B. Wegener’s granulomatosis with orbital involvement: case report and literature review. Rom J Ophthalmol. 2021;65(1):93–97. https://doi.org/10.22336/rjo.2021.19.; Толстов ПВ, Жукова СИ, Калягин АН, Александрова ЮВ, Максикова ТМ, Рыжкова ОВ, Синьков АВ. Гранулематоз с полиангиитом, осложненный поражением придаточного аппарата глаза и сосудистыми изменениями сетчатки и хориоидеи (обзор литературы с клиническим случаем). Acta Biomedica Scientifica. 2024;9(2):172–182. https://doi.org/10.29413/ABS.2024-9.2.17.; Tugal-Tutkun I. Systemic vasculitis and the eye. Curr Opin Rheumatol. 2017;29(1):24–32. https://doi.org/10.1097/BOR.0000000000000345.; Hibino M, Kondo T. Dacryoadenitis with ptosis and diplopia as the initial presentation of granulomatosis with polyangiitis. Intern Med. 2017;56(19):2649–2653. https://doi.org/10.2169/internalmedicine.; Исмаилова ДС, Абрамова ЮВ, Новиков ПИ, Груша ЯО, Лазарчук АВ. Методика ранней диагностики рецидивов у пациентов с поражением орбиты при гранулематозе с полиангиитом (Вегенера). Офтальмология. Восточная Европа. 2023;13(2):141–150. https://doi.org/10.34883/PI.2023.13.2.016.; Егорова ОН, Харламова ЕН, Тарасова ГМ. Дифференциальная диагностика локальной формы гранулематоза с полиангиитом: поражение органа зрения и органа слуха (часть 2). Современная ревматология. 2023;17(2):7–15. https://doi.org/10.14412/1996-7012-2023-2-7-15.

  12. 12
  13. 13
  14. 14
  15. 15
    Academic Journal

    Source: Вестник Бурятской государственной сельскохозяйственной академии имени В. Р. Филиппова. :42-48

  16. 16
    Academic Journal

    Contributors: The study was carried out with infrastructure support of the Kazan Federal University Strategic Academic Leadership Program (Priority-2030). The work was supported by the Russian Science Foundation grant (grant No. 23-15-00456, https://rscf.ru/project/23-15-00456/)., Исследование выполнено при инфраструктурной поддержке Программы стратегического академического лидерства Казанского (Приволжского) федерального университета («Приоритет-2030»). Работа выполнена за счет гранта Российского научного фонда (грант № 23-15-00456, https://rscf.ru/project/23-15-00456/).

    Source: Advances in Molecular Oncology; Vol 11, No 4 (2024); 114-126 ; Успехи молекулярной онкологии; Vol 11, No 4 (2024); 114-126 ; 2413-3787 ; 2313-805X

    File Description: application/pdf

  17. 17
  18. 18
  19. 19
    Academic Journal

    Authors: Melkonyan, Luiza

    Source: Bulletin of Yerevan University B: Philology; Vol. 15 No. 3 (45) (2024); 111-122 ; Բանբեր Երեւանի համալսարանի. Բանասիրություն; Vol. 15 No. 3 (45) (2024); 111-122 ; Բանբեր Երևանի համալսարանի. Բանասիրություն; Vol. 15 No. 3 (45) (2024); 111-122 ; Вестник Ереванского Университета: Филология; Том 15 № 3 (45) (2024); 111-122 ; 2738-2575 ; 1829-457X ; 10.46991/BYSU:B/2024.15.3

    File Description: application/pdf

  20. 20
    Academic Journal

    Source: Urology Herald; Том 12, № 5 (2024); 85-91 ; Вестник урологии; Том 12, № 5 (2024); 85-91 ; 2308-6424 ; 10.21886/2308-6424-2024-12-5

    File Description: application/pdf

    Relation: https://www.urovest.ru/jour/article/view/961/601; Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(12):1529-1554. DOI:10.6004/jnccn.2019.0058; Khatwa UA, Menon PS. Management of undescended testis. Indian J Pediatr. 2000;67(6):449-454. DOI:10.1007/BF02859466; Winter C, Albers P. Testicular germ cell tumors: pathogenesis, diagnosis and treatment. Nat ReV Endocrinol. 2011;7(1):43-53. DOI:10.1038/nrendo.2010.196; Rodprasert W, Virtanen HE, Mäkelä JA, Toppari J. Hypogonadism and Cryptorchidism. Front Endocrinol (Lausanne). 2020;10:906. DOI:10.3389/fendo.2019.00906; Lee PA, Houk CP, Ahmed SF, Hughes IA; International Consensus Conference on Intersex organized by the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. Consensus statement on management of intersex disorders. International Consensus Conference on Intersex. Pediatrics. 2006;118(2):e488-500. DOI:10.1542/peds.2006-0738; Öçal G. Current concepts in disorders of sexual development. J Clin Res Pediatr Endocrinol. 2011;3(3):105-114. DOI:10.4274/jcrpe.v3i3.22; Picard JY, Josso N. Persistent Müllerian duct syndrome: an update. Reprod Fertil DeV. 2019;31(7):1240-1245. DOI:10.1071/RD17501; Minhas S, Bettocchi C, Boeri L, Capogrosso P, Carvalho J, Cilesiz NC, Cocci A, Corona G, Dimitropoulos K, Gül M, Hatzichristodoulou G, Jones TH, Kadioglu A, Martínez Salamanca JI, Milenkovic U, Modgil V, Russo GI, Serefoglu EC, Tharakan T, Verze P, Salonia A; EAU Working Group on Male Sexual and Reproductive Health. European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2021 Update on Male Infertility. Eur Urol. 2021;80(5):603-620. DOI:10.1016/j.eururo.2021.08.014; https://www.urovest.ru/jour/article/view/961